MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
CareDx, Inc Interest Expense 2011-2025 | CDNA
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense CareDx, Inc
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.34 M | -2.87 M | -2.63 M | -811 K | -719 K | -178 K | -1.03 M | -1.92 M | -188 K | -78 K | -536 K | -14 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.34 M | -2.87 M | -803 K |
Quarterly Interest Expense CareDx, Inc
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -107 K | 72 K | 295 K | - | 283 K | -100 K | -290 K | - | 2.05 M | -271 K | -1.97 M | - | -572 K | -553 K | -823 K | - | -3.44 M | 2.78 M | -245 K | - | -254 K | -255 K | -63 K | - | -398 K | -172 K | -74 K | - | -40 K | -42 K | -3 K | - | -317 K | -188 K | -686 K | - | 568 K | 526 K | 266 K | - | 251 K | 256 K | 827 K | - | 355 K | 366 K | -529 K | - | -1 K | -5 K | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.78 M | -3.44 M | -66.1 K |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M |  USA |
|
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Castle Biosciences
CSTL
|
1 K | $ 38.85 | 2.32 % | $ 1.08 B | USA |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
1.54 M | $ 16.36 | -4.05 % | $ 176 M |  China |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
Danaher Corporation
DHR
|
-56 M | $ 227.08 | -2.28 % | $ 166 B | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | $ 101.58 | 0.21 % | $ 18.8 B | USA |
 |
Fulgent Genetics
FLGT
|
561 K | $ 27.13 | 0.26 % | $ 820 M | USA |
 |
BioNano Genomics
BNGO
|
-10.1 M | $ 1.63 | -2.11 % | $ 2.07 M | USA |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
DexCom
DXCM
|
20.3 M | $ 66.91 | -2.94 % | $ 25.8 B | USA |
 |
DarioHealth Corp.
DRIO
|
-31 K | $ 11.92 | -6.58 % | $ 338 M |  Israel |
 |
Illumina
ILMN
|
-292 M | $ 134.29 | -1.58 % | $ 21.4 B | USA |
 |
IQVIA Holdings
IQV
|
670 M | $ 221.54 | -1.96 % | $ 40.2 B | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
Lantheus Holdings
LNTH
|
37.2 M | $ 66.11 | 4.76 % | $ 4.57 B | USA |
 |
Guardant Health
GH
|
-42.6 M | $ 102.09 | 0.7 % | $ 12.5 B | USA |
 |
Celcuity
CELC
|
2.11 M | $ 105.26 | 4.46 % | $ 4.15 B | USA |
 |
Anixa Biosciences
ANIX
|
500 K | $ 3.59 | -25.21 % | $ 115 K | USA |
 |
Co-Diagnostics
CODX
|
106 K | $ 0.34 | -2.96 % | $ 9.98 M | USA |
 |
Myriad Genetics
MYGN
|
1.1 M | $ 7.26 | -0.62 % | $ 658 M | USA |
 |
Neogen Corporation
NEOG
|
38.1 M | $ 6.86 | -2.63 % | $ 1.49 B | USA |
 |
National Research Corporation
NRC
|
862 K | $ 17.81 | 2.24 % | $ 437 M | USA |
 |
Invitae Corporation
NVTA
|
56.7 M | - | - | $ 21.2 M | USA |
 |
Aspira Women's Health
AWH
|
106 K | - | -6.19 % | $ 10.5 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
208 M | $ 263.51 | -0.46 % | $ 22.1 B | USA |
 |
Organovo Holdings
ONVO
|
6 K | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
7.56 K | - | -16.95 % | $ 1.54 M | USA |
 |
Pacific Biosciences of California
PACB
|
14.3 M | $ 2.13 | -1.61 % | $ 540 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
288 M | $ 26.6 | -1.52 % | $ 20 B |  Niderland |
 |
Psychemedics Corporation
PMD
|
17 K | - | -1.84 % | $ 15.3 M | USA |
 |
Charles River Laboratories International
CRL
|
-16.5 M | $ 192.57 | -0.96 % | $ 9.89 B | USA |
 |
Quotient Limited
QTNT
|
2.72 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
RadNet
RDNT
|
24.9 M | $ 75.0 | -4.65 % | $ 5.48 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
30 M | $ 182.21 | 0.35 % | $ 20.2 B | USA |
|
Biodesix
BDSX
|
8.26 M | $ 7.94 | -1.0 % | $ 1.03 B | USA |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 186.28 | -1.92 % | $ 15.4 B |  Irlanda |